By Colin Kellaher


Novartis AG and Roche Holding AG's Genentech unit on Tuesday said the Food and Drug Administration approved the expanded use of Xolair for the add-on maintenance treatment of nasal polyps in adults with inadequate response to intranasal corticosteroids.

The companies said the approval makes Xolair the first biologic for the treatment of nasal polyps that targets and blocks immunoglobulin E, a key driver of inflammation.

Nasal polyps, which can lead to nasal congestion and a loss of smell, frequently occur with other respiratory conditions, such as allergies and asthma.

Xolair was already approved in the U.S. to treat moderate to severe persistent allergic asthma and chronic idiopathic urticaria. Novartis and Genentech work together to develop and co-promote Xolair in the U.S.


Write to Colin Kellaher at


(END) Dow Jones Newswires

December 01, 2020 12:11 ET (17:11 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.